Approved Wire coverage, newest first. Market moves and thesis evidence remain separate.
Equinox Gold posted strong Q2 2026 results, raised full-year production guidance after closing the Orla Mining merger, and hiked its quarterly dividend by 50%. The combination signals management confidence in integration synergies and free cash flow durability at current gold prices.
Allstate reported EPS that beat consensus by $3.72 with revenue also topping estimates, extending a year with FY revenue of $67.7B (+5.6% YoY) and net margin near 15.0% on $38.06 diluted EPS. The beat sets up a test of whether underwriting and pricing gains can keep outpacing claims inflation into the next print.
AMD shares fell after its latest earnings as analysts flagged muted upside, a softer margin outlook, and results that couldn't clear elevated expectations. The stock's post-print drop despite continued growth highlights how priced-for-perfection semis names get punished on any hint of deceleration.
Activist investor Starboard Value has taken a stake in Shake Shack, according to a source, setting up potential pressure for operational or strategic changes at the burger chain. Shake Shack posted $1.4B in revenue (+15.4% YoY) with a thin 3.4% net margin and $1.09 diluted EPS, leaving ample room for an activist to push margin-improvement or capital-allocation arguments.
Booking Holdings posted profit that beat estimates but flagged Middle East geopolitical risk as a drag on its forward outlook. The stock's reaction will hinge on how much the guidance caution offsets the earnings beat.
Uber shares fell after forward bookings guidance came in below expectations, overshadowing the quarter's headline results. CEO Dara Khosrowshahi is leaning on robotaxi partnerships as the next growth lever, setting up a debate over near-term deceleration versus long-term platform optionality.
Disney shares rose after 'Toy Story 5' drove strong box office results and US theme parks showed a rebound, prompting the company to increase its buyback plan. The combination of content strength and parks recovery gives Disney a case for renewed operating momentum heading into its next fiscal reporting.
Bodycote has received competing takeover bids from private equity firms CVC and Veritas, valuing the FTSE 250 industrials group at roughly £1.8bn including debt. The dual bid situation sets up a potential bidding war and adds to a wave of PE interest in undervalued London-listed companies.
Eli Lilly reported revenue up 48% year-over-year, powered by surging demand for GLP-1 drugs Mounjaro and Zepbound. The results beat expectations, reinforcing Lilly's position as a dominant force in the diabetes/obesity drug category.
CVS beat on Q2 earnings but shares slid after management flagged a cautious 2027 outlook, overshadowing the near-term print. FY revenue of $402.1B (+7.8% YoY) shows top-line growth intact, but net margin remains razor-thin at 0.4%, keeping the market focused on forward earnings power rather than the beat.
Cencora's Q3 fiscal 2026 slides point to continued specialty pharmaceutical strength and management raised full-year guidance. The print reinforces the low-margin, high-volume distribution model where top-line growth ($321.3B revenue, +9.3% YoY) matters less than incremental specialty mix and cost discipline holding through year-end.
Wynn Resorts topped quarterly estimates on strength in its Macau operations and disclosed an opening date for its long-awaited UAE casino resort. The UAE launch introduces a new growth vector beyond the mature Macau/Vegas base, giving investors a fresh catalyst to underwrite forward multiples.
Novo Nordisk reported Q2 2026 adjusted operating profit of DKK 33,389 million and raised its full-year outlook. The guidance hike signals management sees continued strength in GLP-1 demand outpacing prior expectations, a key data point after a stretch of intensified competition from Eli Lilly and pricing pressure narratives.